Title | Dermatologic infections in cancer patients treated with checkpoint inhibitors. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Do MH, Barrios DM, Phillips GS, Postow MA, Warner ABetof, Rosenberg JE, Noor SJ, Markova A, Lacouture ME |
Journal | J Am Acad Dermatol |
Date Published | 2021 Mar 17 |
ISSN | 1097-6787 |
Abstract | BACKGROUND: The incidence of dermatologic infections in patients receiving checkpoint inhibitors (CPIs) has not been systematically described. OBJECTIVE: Identify the incidence of dermatologic infections in patients who received CPIs. METHODS: Retrospective review of dermatologic infections in patients who received CPIs between 2005 and 2020 and were evaluated by dermatologists at Memorial Sloan Kettering Cancer Center. RESULTS: Of 2061 patients in the study, 1292 were actively receiving CPIs (≤ 90 days since the last dose) and 769 had previously been on CPIs (> 90 days since the last dose). The dermatologic infection rate was significantly higher in patients with active CPI treatment (17.5%) than in patients not actively being treated (8.2%; P < .0001). In patients on CPIs, 82 (36.2%), 78 (34.5%), and 48 (21.2%) had bacterial, fungal, and viral infections, respectively, and 18 (8.0%) had polymicrobial infections. Anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy was associated with the highest risk of infection (hazard ratio, 2.93; 95% confidence interval, 1.87 to 4.60; P < .001). LIMITATIONS: Retrospective design and sample limited to patients referred to dermatology. CONCLUSIONS: Patients actively receiving CPIs are more susceptible to dermatologic infections, with anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy carrying the highest risk, suggesting that the index of suspicion for infections should be increased in these patients to minimize morbidity and optimize care. |
DOI | 10.1016/j.jaad.2021.03.039 |
Alternate Journal | J Am Acad Dermatol |
PubMed ID | 33744355 |
Grant List | U01 AR077511 / AR / NIAMS NIH HHS / United States |
Submitted by bel2021 on April 20, 2021 - 3:20pm